Pyxis Oncology Stock Analysis
| PYXS Stock | USD 1.89 0.01 0.53% |
Pyxis Oncology is undervalued with Real Value of 3.82 and Hype Value of 1.9. The main objective of Pyxis Oncology stock analysis is to determine its intrinsic value, which is an estimate of what Pyxis Oncology is worth, separate from its market price. There are two main types of Pyxis Oncology's stock analysis: fundamental analysis and technical analysis.
The Pyxis Oncology stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Pyxis Oncology is usually not traded on Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday. Pyxis Stock trading window is adjusted to America/New York timezone.
Pyxis |
Pyxis Stock Analysis Notes
About 25.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.74. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Pyxis Oncology has Price/Earnings To Growth (PEG) ratio of 0.01. The entity recorded a loss per share of 1.06. The firm had not issued any dividends in recent years. Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. Pyxis Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 67 people. To find out more about Pyxis Oncology contact MBA MD at 617 221 9059 or learn more at https://www.pyxisoncology.com.Pyxis Oncology Investment Alerts
| Pyxis Oncology generated a negative expected return over the last 90 days | |
| Pyxis Oncology has high historical volatility and very poor performance | |
| Pyxis Oncology may become a speculative penny stock | |
| Pyxis Oncology has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (73.79 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Pyxis Oncology currently holds about 223.36 M in cash with (70.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.48, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Pyxis Oncology has a frail financial position based on the latest SEC disclosures | |
| Roughly 25.0% of the company outstanding shares are owned by corporate insiders |
Pyxis Oncology Upcoming and Recent Events
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Pyxis Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 112.98 M.Technical Drivers
As of the 26th of November, Pyxis Oncology holds the Risk Adjusted Performance of (0.07), coefficient of variation of (1,003), and Variance of 51.57. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Pyxis Oncology, as well as the relationship between them. Please check Pyxis Oncology risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and kurtosis to decide if Pyxis Oncology is priced some-what accurately, providing market reflects its current price of 1.89 per share. Please also confirm Pyxis Oncology jensen alpha, which is currently at (0.74) to check out the company can sustain itself at a future point.Pyxis Oncology Price Movement Analysis
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Pyxis Oncology middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Pyxis Oncology. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Pyxis Oncology Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pyxis Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pyxis Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pyxis Oncology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Pyxis Oncology Outstanding Bonds
Pyxis Oncology issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Pyxis Oncology uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Pyxis bonds can be classified according to their maturity, which is the date when Pyxis Oncology has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| QORVO INC 3375 Corp BondUS74736KAJ07 | View | |
| QORVO INC 4375 Corp BondUS74736KAH41 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| QTELQD 2625 08 APR 31 Corp BondUS74735KAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Pyxis Oncology Predictive Daily Indicators
Pyxis Oncology intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Pyxis Oncology stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Pyxis Oncology Forecast Models
Pyxis Oncology's time-series forecasting models are one of many Pyxis Oncology's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Pyxis Oncology's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Pyxis Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Pyxis Oncology prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Pyxis shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Pyxis Oncology. By using and applying Pyxis Stock analysis, traders can create a robust methodology for identifying Pyxis entry and exit points for their positions.
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. Pyxis Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 67 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Pyxis Oncology to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Content Syndication Now
Content SyndicationQuickly integrate customizable finance content to your own investment portal |
| All Next | Launch Module |
Additional Tools for Pyxis Stock Analysis
When running Pyxis Oncology's price analysis, check to measure Pyxis Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pyxis Oncology is operating at the current time. Most of Pyxis Oncology's value examination focuses on studying past and present price action to predict the probability of Pyxis Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pyxis Oncology's price. Additionally, you may evaluate how the addition of Pyxis Oncology to your portfolios can decrease your overall portfolio volatility.